Filtered By:
Management: Government
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 334 results found since Jan 2013.
There's A Strong Chance You Are Paying For Expensive Medical Billing Mistakes
Medical bills are the gift that keeps on giving. Having lost my husband in January, I can attest that not even death puts an end to the steady stream of bills for his care that I still get in the mail. Balance billing, services not covered, out-of-network doctors ― they all come back to haunt you in the form of bills ― including a good number from doctors you’ve never met or heard of, and who you don’t when or why even saw your loved one.
The bills? I expected them. What I didn’t expect was to learn that medical bills notoriously contain errors ― big errors. While there are no comprehensive statisti...
Source: Healthy Living - The Huffington Post - May 17, 2017 Category: Consumer Health News Source Type: news
Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS
NEW YORK (Reuters) - The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
Source: Reuters: Health - May 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Report: Mylan may have overcharged US by $1.3B for EpiPen
Mylan (NSDQ:MYL) shares dipped slightly in mid-afternoon trading today after Sen. Chuck Grassley’s (R-Iowa) office released a Health and Human Services estimate claiming that taxpayers overpaid by as much as $1.27 billion for Mylan’s EpiPen device from 2006 to 2016.
The charges stem from Mylan’s decision to classify the emergency allergy auto-injector as a generic, instead of a branded product under the Medicaid Drug Rebate Program. Misclassifying the device allowed the company to pay the government a 13% rebate instead of a 23% rebate. The Centers for Medicare and Medicaid Services repeatedly warned Mylan that the...
Source: Mass Device - May 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
Mylan May Have Overcharged U.S. For EpiPen By $1.27 Billion
By Michael Erman
NEW YORK (Reuters) - The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
The amount is nearly three times a proposed settlement that the company announced in October.
The analysis on the EpiPen payments, which was conducted by the Department of Health and Human Services’ Office of Inspector General, was released by Republican Senator Chuck Grassley.
“Mylan and the Obama Administration reportedly were close to settling the overpayment...
Source: Healthy Living - The Huffington Post - June 1, 2017 Category: Consumer Health News Source Type: news
Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients
AbstractThe effect of biologic disease modifying anti-rheumatic drugs (bDMARDs) in treating rheumatoid arthritis (RA) in real-world clinical practice remains unknown in Southeast Asia. We aimed to assess the efficacy and safety of bDMARDs among Malaysian RA patients treated in routine clinical practice. A retrospective medical chart review of RA patients from 11 government hospitals were conducted from January 2003 to January 2014. A standardized questionnaire was used to abstract patient ’s demographic, clinical and treatment data. Level of disease activity was measured by DAS28 collected at baseline, 3, 6 and 12 month...
Source: Rheumatology International - July 10, 2017 Category: Rheumatology Source Type: research
US Lags Far Behind in Banning Dental Health Hazard
Example of mercury use in the healthcare sector. From left to right: Mercury Sphygmomanometer, Dental Amalgam and a Fever Thermometer. Credit: UNDPBy Thalif DeenUNITED NATIONS, Jul 31 2017 (IPS)The United States is lagging far behind its Western allies – and perhaps most of the key developing countries – in refusing to act decisively to end a longstanding health and environmental hazard: the use of mercury in dentistry. The 28-member European Union (EU), with an estimated population of over 510 million people, recently announced its decision to ban amalgam use in children under age 15, pregnant women, and breastfeeding...
Source: IPS Inter Press Service - Health - July 31, 2017 Category: International Medicine & Public Health Authors: Thalif Deen Tags: Environment Featured Global Global Governance Headlines Health Inequity IPS UN: Inside the Glasshouse Population Regional Categories Sustainability TerraViva United Nations Source Type: news
Food allergen extracts to diagnose food-induced allergic diseases
To review the manufacturing procedures of food allergen extracts and applicable regulatory requirements from government agencies, potential approaches to standardization, and clinical application of these products. The effects of thermal processing on allergenicity of common food allergens are also considered.
Source: Annals of Allergy, Asthma and Immunology - August 1, 2017 Category: Allergy & Immunology Authors: Natalie A. David, Anusha Penumarti, A. Wesley Burks, Jay E. Slater Tags: How Allergen Extracts Are Made —From Source Materials to Allergen Extracts Source Type: research
Mylan, U.S. finalize $465 million EpiPen settlement
BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.
Source: Reuters: Health - August 17, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
EpiPen maker settles federal claims for $465M a year after Sanofi filed suit
Mylan NV will pay $465 million fine to settle claims brought by the U.S. Justice Department that it overcharged the government for its emergency allergy drug, EpiPen.
The U.S. Attorney’s Office in Massachusetts announced the agreement on Thursday, saying it had violated the False Claims Act “by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.”
French drug company Sanofi , the parent company of the state’s…
Source: bizjournals.com Health Care:Physician Practices headlines - August 17, 2017 Category: American Health Authors: Don Seiffert Source Type: news
Pa. to get $8.3M in Mylan EpiPen settlement
Pennsylvania will receive $8.3 million from the settlement between Mylan NV and the U.S. Department of Justice over EpiPen pricing.
The settlement, announced Thursday, involves the federal government's claims that it was overcharged for the anti-allergy treatment under Medicaid programs. Mylan did not acknowledge wrongdoing but agreed to the $456 million settlement.
"As we said when we announced the settlement last year, brin ging closure to this matter is the right course of action for Mylan and…
Source: bizjournals.com Health Care News Headlines - August 18, 2017 Category: Health Management Authors: Paul J. Gough Source Type: news
Experts Concerned About Effectiveness Of This Year ’ s Flu Vaccine
(CNN) — Last year’s seasonal flu vaccine effectiveness was just 42%, the US Centers for Disease Control and Prevention estimated. Even if vaccinated, people had inadequate protection against the flu.
This limited effectiveness was due to a mutation that occurred in the influenza A (H3N2) vaccine strain, according to a study published Monday in the journal Proceedings of the National Academy of Sciences. This vaccine mutation resulted from an egg-based manufacturing process commonly used today.
This year’s flu vaccine may also be imperfect, said Scott Hensley, author of the new study and an associate profe...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 8, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Flu Flu Vaccine Local TV Source Type: news
What Recent History Has Taught Us About Responding to Emerging Infectious Disease Threats.
This article recounts selected outbreaks occurring during this period and highlights lessons that were learned that can be applied to the infectious disease threats that will inevitably be faced in the current presidential administration and beyond.
PMID: 29132162 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - November 14, 2017 Category: Internal Medicine Authors: Paules CI, Eisinger RW, Marston HD, Fauci AS Tags: Ann Intern Med Source Type: research
Gene-Based Zika Vaccine is Safe and Immunogenic in Healthy Adults
Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults.
Source: PHPartners.org - December 5, 2017 Category: International Medicine & Public Health Source Type: news
Gene-based Zika vaccine is safe and immunogenic in healthy adults
Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.
Source: World Pharma News - December 5, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
